Biosergen appoints Mangold Fondkommission to act as a liquidity provider

Report this content

Biosergen AB (publ) (“Biosergen” or the “Company”) has appointed Mangold Fondkommission to act as a liquidity provider for the company's share. The liquidity providing will begin on Wednesday, October 5th, 2022.

Mangold Fondkommission will fulfil its mandate as a liquidity provider to continuously place trading posts on each buy and sell side in the Biosergen share booklet and ensure that a predetermined spread is held in the share. The purpose of the liquidity providing is to promote good liquidity and ensure a low spread between buy and sell prices in current trading.

For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470

Certified Adviser
Erik Penser Bank
Telephone: +46 8 463 8000

Biosergen is a No-Research-Development-Only biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States.


Documents & Links